Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
Background and Introduction: Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle, typically presenting unilaterally with ipsilateral sensorineural hearing loss (SNHL). The mechanism of tumor-induced hearing loss has recently been shown to be related to secreted tumo...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00796/full |
id |
doaj-18c9235969414559830b48370e4ec83c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Samuel Early Samuel Early Samuel Early Charlotte E. Rinnooy Kan Charlotte E. Rinnooy Kan Charlotte E. Rinnooy Kan Maura Eggink Maura Eggink Maura Eggink Johan H. M. Frijns Johan H. M. Frijns Johan H. M. Frijns Konstantina M. Stankovic Konstantina M. Stankovic Konstantina M. Stankovic Konstantina M. Stankovic |
spellingShingle |
Samuel Early Samuel Early Samuel Early Charlotte E. Rinnooy Kan Charlotte E. Rinnooy Kan Charlotte E. Rinnooy Kan Maura Eggink Maura Eggink Maura Eggink Johan H. M. Frijns Johan H. M. Frijns Johan H. M. Frijns Konstantina M. Stankovic Konstantina M. Stankovic Konstantina M. Stankovic Konstantina M. Stankovic Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma Frontiers in Neurology vestibular schwannoma hearing loss contralateral secreted factors outcomes |
author_facet |
Samuel Early Samuel Early Samuel Early Charlotte E. Rinnooy Kan Charlotte E. Rinnooy Kan Charlotte E. Rinnooy Kan Maura Eggink Maura Eggink Maura Eggink Johan H. M. Frijns Johan H. M. Frijns Johan H. M. Frijns Konstantina M. Stankovic Konstantina M. Stankovic Konstantina M. Stankovic Konstantina M. Stankovic |
author_sort |
Samuel Early |
title |
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma |
title_short |
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma |
title_full |
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma |
title_fullStr |
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma |
title_full_unstemmed |
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma |
title_sort |
progression of contralateral hearing loss in patients with sporadic vestibular schwannoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2020-08-01 |
description |
Background and Introduction: Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle, typically presenting unilaterally with ipsilateral sensorineural hearing loss (SNHL). The mechanism of tumor-induced hearing loss has recently been shown to be related to secreted tumor factors, in addition to mechanical compression of the adjacent auditory nerve, and these factors may percolate through CSF or blood to affect contralateral hearing as well.Methods: This is a retrospective study of medical records for patients treated for VS at Mass Eye and Ear from January 1994 through October 2018. Included patients had unilateral VS and sequential audiometry allowing for longitudinal assessment of hearing over time. Mass Eye and Ear's audiology database was used to select age- and sex-matched case controls, also with sequential audiometry, from the non-VS population. Subgroup analysis was performed by age, sex, baseline hearing, and tumor size at initial diagnosis. Hearing loss progression was performed using Kaplan-Meier analysis to account for variable follow-up times.Results: A total of 661 patients were identified with VS and sequential audiometry. The population was predominantly female vs. male (368 vs. 293, p = 0.0035), driven primarily by younger patients with Koos 4 tumors (76 female vs. 49 male, p = 0.016). Patients with normal baseline hearing bilaterally (N = 241) demonstrated no significant difference in hearing loss progression in VS-contralateral vs. control ears. Patients with abnormal baseline VS-ipsilateral hearing (N = 190), however, demonstrated significantly higher likelihood of reaching moderate SNHL in VS-contralateral ears. Subgroup analysis by age, sex, and baseline tumor size did not yield any subgroup-specific trends for hearing loss progression.Discussion and Conclusion: This is the largest study to date tracking long-term bilateral hearing outcomes in patients with VS, and demonstrates that, in patients with abnormal hearing in the VS-ipsilateral ear, there exists a long-term risk of progression to moderate hearing loss in the contralateral ear as well. Combined with the absence of significant changes in word understanding in the affected ears, these findings may provide clues to the nature of tumor-secreted factors involved in VS-associated hearing loss. Female predominance within the VS patient population is confirmed, driven mostly by younger female patients with Koos 4 tumors. |
topic |
vestibular schwannoma hearing loss contralateral secreted factors outcomes |
url |
https://www.frontiersin.org/article/10.3389/fneur.2020.00796/full |
work_keys_str_mv |
AT samuelearly progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT samuelearly progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT samuelearly progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT charlotteerinnooykan progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT charlotteerinnooykan progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT charlotteerinnooykan progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT mauraeggink progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT mauraeggink progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT mauraeggink progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT johanhmfrijns progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT johanhmfrijns progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT johanhmfrijns progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma |
_version_ |
1724604150594928640 |
spelling |
doaj-18c9235969414559830b48370e4ec83c2020-11-25T03:23:59ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-08-011110.3389/fneur.2020.00796549971Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular SchwannomaSamuel Early0Samuel Early1Samuel Early2Charlotte E. Rinnooy Kan3Charlotte E. Rinnooy Kan4Charlotte E. Rinnooy Kan5Maura Eggink6Maura Eggink7Maura Eggink8Johan H. M. Frijns9Johan H. M. Frijns10Johan H. M. Frijns11Konstantina M. Stankovic12Konstantina M. Stankovic13Konstantina M. Stankovic14Konstantina M. Stankovic15Eaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesSan Diego School of Medicine, University of California, San Diego, San Diego, CA, United StatesEaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesLeiden University Medical Center, Leiden, NetherlandsEaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesUniversity Medical Center Groningen, Groningen, NetherlandsLeiden University Medical Center, Leiden, NetherlandsDepartment of Otolaryngology—Head and Neck Surgery, Leiden University Medical Center, Leiden, NetherlandsLeiden Institute for Brain and Cognition, Leiden, NetherlandsEaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesProgram in Speech and Hearing Bioscience and Technology, Harvard Medical School, Boston, MA, United StatesHarvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, United StatesBackground and Introduction: Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle, typically presenting unilaterally with ipsilateral sensorineural hearing loss (SNHL). The mechanism of tumor-induced hearing loss has recently been shown to be related to secreted tumor factors, in addition to mechanical compression of the adjacent auditory nerve, and these factors may percolate through CSF or blood to affect contralateral hearing as well.Methods: This is a retrospective study of medical records for patients treated for VS at Mass Eye and Ear from January 1994 through October 2018. Included patients had unilateral VS and sequential audiometry allowing for longitudinal assessment of hearing over time. Mass Eye and Ear's audiology database was used to select age- and sex-matched case controls, also with sequential audiometry, from the non-VS population. Subgroup analysis was performed by age, sex, baseline hearing, and tumor size at initial diagnosis. Hearing loss progression was performed using Kaplan-Meier analysis to account for variable follow-up times.Results: A total of 661 patients were identified with VS and sequential audiometry. The population was predominantly female vs. male (368 vs. 293, p = 0.0035), driven primarily by younger patients with Koos 4 tumors (76 female vs. 49 male, p = 0.016). Patients with normal baseline hearing bilaterally (N = 241) demonstrated no significant difference in hearing loss progression in VS-contralateral vs. control ears. Patients with abnormal baseline VS-ipsilateral hearing (N = 190), however, demonstrated significantly higher likelihood of reaching moderate SNHL in VS-contralateral ears. Subgroup analysis by age, sex, and baseline tumor size did not yield any subgroup-specific trends for hearing loss progression.Discussion and Conclusion: This is the largest study to date tracking long-term bilateral hearing outcomes in patients with VS, and demonstrates that, in patients with abnormal hearing in the VS-ipsilateral ear, there exists a long-term risk of progression to moderate hearing loss in the contralateral ear as well. Combined with the absence of significant changes in word understanding in the affected ears, these findings may provide clues to the nature of tumor-secreted factors involved in VS-associated hearing loss. Female predominance within the VS patient population is confirmed, driven mostly by younger female patients with Koos 4 tumors.https://www.frontiersin.org/article/10.3389/fneur.2020.00796/fullvestibular schwannomahearing losscontralateralsecreted factorsoutcomes |